ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1651

Multicenter Double-Blind, Proof-of-Concept, Randomized Placebo-Controlled Trial of Riociguat in Systemic Sclerosis-associated Digital Ulcers

Vivek Nagaraja1, Cathie Spino 1, Pei-Suen Tsou 1, Robyn Domsic 2, Robert Lafyatis 2, Tracy Frech 3, Jessica Gordon 4, Virginia Steen 5 and Dinesh Khanna 6, 1University of Michigan, Ann Arbor, MI, 2University of Pittsburgh, Pittsburgh, PA, 3Division of Rheumatology, University of Utah and Salt Lake VAMC, Salt Lake City, UT, 4Hospital for Special Surgery, New York, NY, 5Georgetown University, Washington, D.C., USA, Georgetown, 6Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Systemic sclerosis, ulcers and clinical trials

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 11, 2019

Session Title: Systemic Sclerosis & Related Disorders – Clinical Poster II

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: The soluble guanylate cyclase stimulator riociguat (RIO) is a vasodilator with efficacy in patients with pulmonary arterial hypertension associated with connective tissue disease. Our objective was to evaluate the efficacy and safety of RIO in patients with systemic sclerosis-associated digital ulcers (SSc-DU) (NCT02915835).

Methods: Eligible subjects (with active or painful indeterminate DUs) were randomized in a 1:1 ratio to either placebo (PLA, n = 8) or RIO (n = 9) in individualized doses (maximum of 2.5 mg three times daily) during an 8-week titration period, followed by an 8-week stable dosing period.PDE5 inhibitors were not allowed. This was followed by an optional 16-week open-label extension phase for participants with active DUs / reoccurrence of DUs within 1 month of the end of the main treatment phase. The primary endpoint was the change from baseline to week 16 in net ulcer burden (NUB), analyzed using ANCOVA. Other endpoints included plasma biomarkers and the proportion of participants with treatment-emergent adverse events (AEs).

Results: We randomized 17 participants with SSc-DUs at 5 US centers between January 2017 and March 2018. Six participants in each group progressed transitioned to the open-label extension phase. Baseline characteristics were comparable between treatment groups, except participants randomized to PLA were older (mean 61 vs. 43 yrs) with longer disease duration (mean 17.5 vs. 7.1 yrs). At baseline, the mean (SD) NUB was 2.5 (2.0) in the PLA and 2.4 (1.4) in the RIO. No significant difference was observed between RIO and PLA in change from baseline to 16 weeks in NUB  [treatment difference -0.24 favoring RIO, p=0.70; Figure 1].  In the open-label extension, participants in the RIO-RIO arm had complete healing of their DUs.There were no statistically significant treatment differences in secondary efficacy endpoints, except for the eating component of HAQ-DI (Table 1). All 17 participants reported ≥1 adverse event, with the vast majority being mild or moderate. Four participants experienced 5 serious AE (4 in RIO and 1 in PLA); none was considered related to study medication. Statistically significant elevations of cGMP were observed at 16 weeks [treatment difference 157.3 nM, p=0.05, Figure 2]; no other biomarkers showed statistically significant changes.

Conclusion: In participants with SSc-DU, treatment with RIO did not reduce the number of DU net burden compared with PLA. Open-label extension suggests that a longer duration is needed to promote DU healing, which needs to be confirmed within a new trial. 

The negative results may reflect a small number of patients, low number of NUB at baseline, moderate-to-severe vasculopathy with long term disease, and the difficulty to recruit patients in the era of widespread use of PDE5 inhibitors.

Figure 1: Mean Trend Over Time: Change in Net Ulcer Burden

Table 1: Changes from baseline to week 16 in primary and secondary efficacy endpoints

Figure 2: Plasma biomarker changes from baseline -week 0- to week 16


Disclosure: V. Nagaraja, None; C. Spino, None; P. Tsou, None; R. Domsic, Boehringer Ingelheim, 5, Boehringer-Ingelheim, 5, Eicos, 5, EICOS Sciences Inc, 5; R. Lafyatis, PRISM Biolab, 2, MERCK, 5, Bristol-Myers Squibb, 5, Regeneron, 2, Elpidera, 2, Kiniksa, 2, Biocon, 5, UCB, 5, Formation, 5, Sanofi, 5, Genentech / Roche, 5; T. Frech, None; J. Gordon, Corbus, 2, Corbus Pharmaceuticals, 2, Cumberland, 2, Cumberland Pharmaceuticals, 2, Elcos, 2; V. Steen, Boehringer Ingelheim, 5, Corbus, 5, 9, CSL, 5, 9, CSL Behring, 2, 5, DSMB, 5, 9, Galapagos, 5, 9; D. Khanna, Acceleron, 5, 8, Acceleron Pharma, 5, Actelion, 5, 8, Actelion Pharmaceuticals, 5, Astra Zeneca, 5, Bayer, 2, 5, 8, Behring, 5, Blade, 5, Blade Therapeutics, 5, 8, Blade therapeutics, 5, BMS, 2, 5, 8, Boehringer Ingelham, 5, Boehringer Ingelheim, 5, 8, Boehringer-Ingelheim, 5, Bristol Myers Squibb, 2, 5, Bristol-Myers Squibb, 2, 5, Celegene, 5, Celgene, 5, 8, ChemomAB, 5, ChemomAb, 5, CiviBioPharma, Inc., 3, Corbus, 5, Corobus, 5, Corpus, 5, CSL Behring, 5, 8, Curizon, 5, Curzion, 5, Cytori, 5, 8, Eicos, 4, Eicos Sciences, 4, Eicos Sciences, Inc, 4, Eicos Sciences, Inc/ CiviBioPharma, Inc, 1, 4, Eicos Sciences, Inc/ CiviBioPharma, Inc., 1, Eicos, Inc, 4, Eicos, Inc., 5, 8, Eicos, INC., 4, Galapagos, 5, Genentech, 5, Genentech/Roche, 5, GlaxoSmithKline, 5, GSK, 5, Horizon, 2, 5, Mitsubishi Tanabe Pharma, 5, Mitsubishi Tanabe Pharma Dev America, 5, Mitsubishi Tanabe Pharma Development America, 5, Mitsubishi Tanabi, 5, NIH K24 and R01, 2, NIH / NIAMS K24 AR-063120, 2, NIH/NIAMS R01& K24, 2, Pfizer, 2, 5, Sanofi, 5, Sanofi Aventis, 5, Sanofi-Aventis, 5, 8, Sanofi-Aventis/Genzyme, 5, UCB, 5, UCB Pharma, 5.

To cite this abstract in AMA style:

Nagaraja V, Spino C, Tsou P, Domsic R, Lafyatis R, Frech T, Gordon J, Steen V, Khanna D. Multicenter Double-Blind, Proof-of-Concept, Randomized Placebo-Controlled Trial of Riociguat in Systemic Sclerosis-associated Digital Ulcers [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/multicenter-double-blind-proof-of-concept-randomized-placebo-controlled-trial-of-riociguat-in-systemic-sclerosis-associated-digital-ulcers/. Accessed January 27, 2023.
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/multicenter-double-blind-proof-of-concept-randomized-placebo-controlled-trial-of-riociguat-in-systemic-sclerosis-associated-digital-ulcers/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences